HER2CLIMB-05 / SGNTUC-028

Topic of Study: Breast Cancer

Sponsor: Seagen, Inc.

Principal Investigator: David Riseberg, M.D., 410-783-5858

Research Coordinator: Alexandra Cline, RN, 410-951-7956; Meeghan Bey, RN, 410-951-7908

Coordinated Through: Institutional Research

This study is a randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for first line, metastatic HER+2 breast cancer (Clinicaltrials.gov ID#: NCT05132582).